Innocrin Pharmaceuticals' Series D Round

Innocrin Pharmaceuticals raised a round of funding on April 14, 2015.

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally…

Articles about Innocrin Pharmaceuticals' Series D Round: